natgillin/translations-raw huggingface dataset:
The rate of hospitalisations was not increased in FLUENZ recipients 12 months and older.
Stopnja hospitalizacije se pri prejemnikih cepiva FLUENZ starih 12 mesecev ali več ni povišala.
FLUENZ has demonstrated superiority in 3 active-controlled studies with injectable influenza vaccine.
Cepivo FLUENZ je bilo v 3 aktivno kontroliranih študijah s cepivom gripe, ki se injicira, superiorno.
PHARMACEUTICAL FORM AND CONTENTS Nasal spray, suspension
FARMACEVTSKA OBLIKA IN VSEBINA pršilo za nos, suspenzija
Do not use salicylates in children and adolescents younger than 18 years of age for 4 weeks after vaccination unless medically indicated as Reye's syndrome has been reported following the use of salicylates during wild-type influenza infection.
Salicilata se ne sme uporabljati še 4 tedne po cepljenju pri otrocih in mladostnikih starih manj kot 18 let, razen če je to medicinsko indicirano, ker so po uporabi salicilata v času okužbe z gripo virusa divjega tipa poročali o Reyevem sindromu.
In study participants who received 2 doses in year 1 and placebo in year 2, efficacy in year 2 was 56.2% (95% CI: 30.5, 72.7) and 44.8% (95% CI: 18.2, 62.9), respectively, in D153-P501, thus supporting the need for second-season revaccination.
Pri preiskovancih v študiji, ki so 1. leto prejeli 2 odmerka in placebo 2. leto, je bila učinkovitost 2. leto 56,2% (95-% IZ: 30,5; 72,7) oziroma 44,8% (95-% IZ: 18,2; 62,9) pri študiji D153-P501, kar govori v prid potrebi po revakcinaciji v drugi sezoni.
FLUENZ demonstrated 55.7% (39.9, 67.6) fewer cases than injectable influenza vaccine in 3,659 infants and toddlers 6-23 months of age and 54.4% (41.8, 64.5) fewer cases in 4,166 children 24-59 months of age.
c Z cepivom FLUENZ je bilo 55,7% (39,9; 67,6) manj primerov kot pri cepivu proti gripi, ki se injicira, pri 3.659 dojenčkih in malčkih starih od 6-23 mesecev in 54,4% (41,8; 64,5) manj primerov pri 4.166 otrok starih od 24-59 mesecev.
Tell your doctor, nurse or pharmacist if the person being vaccinated is taking, has recently taken or might take any other medicines.
Druga zdravila, druga cepiva in cepivo Fluenz Obvestite svojega zdravnika, medicinsko sestro ali farmacevta, če oseba, ki se cepi, jemlje, je pred kratkim jemala ali pa bo morda začela jemati katero koli drugo zdravilo.
In previously unvaccinated study participants who received one dose in year 1, efficacy was 57.7% (95% CI: 44.7, 67.9) and 56.3% (95% CI: 43.1, 66.7), respectively, thus supporting the need for two doses of vaccine in previously unvaccinated children.
Pri preiskovancih v študiji, ki se pred tem niso cepili in so prejeli le en odmerek v 1. letu, je bila učinkovitost 57,7% (95-% IZ: 44,7; 67,9) oziroma 56,3% (95-% IZ: 43,1; 66,7), to govori v prid potrebi po dveh odmerkih cepiva pri predhodno necepljenih otrocih.
Do not administer FLUENZ to infants and toddlers younger than 12 months.
Cepiva FLUENZ se ne sme uporabiti pri dojenčkih in malčkih mlajših od 12 mesecev.
This vaccine complies with the WHO (World Health Organisation) recommendations (Northern Hemisphere) and EU decision for the 2013/2014 season.
Cepivo ustreza priporočilom Svetovne zdravstvene organizacije (severna polobla) in odločbi EU za sezono 2013/2014.
Table 2 FLUENZ Relative Efficacy in Active-controlled Paediatric Studies with Injectable
Preglednica 2 Relativna učinkovitost cepiva FLUENZ v aktivno kontroliranih pediatričnih študijah s cepivom proti gripi, ki se injicira
• It is recommended that Fluenz is not given at the same time as influenza-specific antiviral medicines.
• Priporoča se, da se cepiva Fluenz ne daje sočasno s protivirusnimi zdravili, specifičnimi za gripo, ker bo cepivo morda manj učinkovito.
The rate of wheezing was not increased in FLUENZ recipients 24 months and older.
Stopnja sopenja se pri prejemnikih cepiva FLUENZ starih 24 mesecev ali več ni povišala.
Figure 1 FLUENZ Administration
Slika 1 Aplikacija cepiva FLUENZ
FLUENZ should not be used in infants and toddlers below 24 months of age because of safety concerns (see section 4.4).
Cepivo FLUENZ se ne sme uporabljati pri dojenčkih in malčkih mlajših od 24 mesecev zaradi pomislekov glede varnosti (glejte poglavje 4.4).
This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2013/2014 season.
Cepivo ustreza priporočilom SZO (Svetovne zdravstvene organizacije) (severna polobla) in odločbi EU za sezono 2013/2014.
NAME OF THE MEDICINAL PRODUCT FLUENZ nasal spray suspension Influenza vaccine (live attenuated, nasal) 2013/2014 season
FLUENZ pršilo za nos, suspenzija cepivo proti gripi (z živimi oslabljenimi virusi, nosno) Sezona 2013/2014
METHOD AND ROUTE(S) OF ADMINISTRATION For nasal use only.
POSTOPEK IN POT(I) UPORABE ZDRAVILA Samo za nazalno uporabo.
b Reduction in culture-confirmed influenza illness relative to injectable influenza vaccine.
Zmanjšanje obolelosti za gripo, potrjene s kulturo, glede na cepivo proti gripi, ki se injicira.
Respiratory, thoracic, and mediastinal disorders Very common: Nasal congestion/rhinorrhoea Uncommon: Epistaxis
Bolezni dihal, prsnega koša in mediastinalnega prostora Zelo pogosti: zamašen nos/rinoreja Občasni: epistaksa
DO NOT INJECT FLUENZ.
CEPIVA FLUENZ NE INJICIRAJTE.
Please read the package leaflet for disposal of medicines no longer required.
Za odstranjevanje zdravil, ki jih več ne potrebujete, preberite navodilo za uporabo.
No clinically meaningful changes in immune responses to measles, mumps, varicella, orally-administered poliovirus or FLUENZ have been observed.
Klinično pomembnih sprememb odziva imunskega sistema na cepivo proti ošpicam, mumpsu, noricam in na peroralno cepivo proti otroški paralizi ali cepivo FLUENZ niso opazili.
If any of these apply, tell your doctor, nurse or pharmacist before vaccination.
Če karkoli od tega velja za vas, obvestite svojega zdravnika, medicinsko sestro ali farmacevta pred cepljenjem.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION FLUENZ
IME ZDRAVILA IN POT(I) UPORABE FLUENZ cepivo proti gripi
6.6 Special precautions for disposal and other handling
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Uporaba cepiva
Efficacy (95% CI)b All strains regardless of match
Učinkovitost (95-% IZ)b Vsi sevi neodvisno od ujemanja
Do not administer FLUENZ to children and adolescents younger than 18 years of age receiving salicylate therapy (see section 4.3).
Cepiva FLUENZ se ne sme uporabiti pri otrocih in mladostnikih mlajših od 18 let, ki se zdravijo s salicilatom (glejte poglavje 4.3).
In a clinical study, an increase in hospitalisations was observed in infants and toddlers younger than 12 months after vaccination (see section 4.8).
V klinični študiji so po cepljenju opazili povečano stopnjo hospitalizacije pri dojenčkih in malčkih mlajših od 12 mesecev (glejte poglavje 4.8).
FLUENZ IS FOR NASAL USE ONLY.
CEPIVO FLUENZ JE SAMO ZA NAZALNO UPORABO.
FLUENZ is not indicated for use in infants and toddlers younger than 24 months (see section 4.4).
Cepivo FLUENZ ni indicirano za uporabo pri dojenčkih in malčkih mlajših od 24 mesecev (glejte poglavje 4.4).
Non-clinical data with FLUENZ reveal no special hazard for humans based on conventional non-clinical studies of repeated dose toxicity, reproduction and developmental toxicity, local tolerance, and neurovirulence.
Predklinični podatki s cepivom FLUENZ na osnovi običajnih študij predklinične varnosti, toksičnosti pri ponavljajočih se odmerkih, vpliva na sposobnost razmnoževanja in razvoja, lokalnega prenašanja in nevrovirulence ne kažejo posebnega tveganja za človeka.
Fluenz must not be injected.
Cepiva Fluenz se ne sme injicirati.
Efficacy (95% CI)
Učinkovitost (95-% IZ)
Contents of the pack and other information
Shranjevanje cepiva Fluenz Vsebina pakiranja in dodatne informacije
Fluenz will be given as a spray in each nostril.
Cepivo Fluenz se daje v obliki pršila v vsako nosnico.
No data exist regarding the safety of intranasal administration of FLUENZ in children with unrepaired craniofacial malformations.
O intranazalnem dajanju cepiva FLUENZ otrokom z nepopravljenimi kraniofacialnimi deformacijami ni podatkov.
• Refer to the FLUENZ administration diagram (Figure 1) for step-by-step administration instructions.
• Za navodila za aplikacijo cepiva FLUENZ po korakih glejte postopek aplikacije (slika 1).
- If you have any further questions, ask your doctor, nurse or pharmacist.
- Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom, medicinsko sestro ali s farmacevtom.
Check expiry date Product must be used before date on applicator label.
Preverite rok uporabnosti Cepivo uporabite pred datumom na oznaki nosnika.
Very rare (may affect up to 1 in 1,000,000 people):
Zelo redki (pojavijo se pri največ 1 od 1.000.000 oseb):
Position the applicator With the patient in an upright position, place the tip just inside the nostril to ensure Fluenz is delivered into the nose.
Namestitev nosnika Ko je oseba v pokončnem položaju, namestite konico nekoliko v nosnico, da zagotovite vnos cepiva Fluenz v nos.
Contents of the pack and other information What Fluenz contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje cepivo Fluenz Zdravilne učinkovine so:
The suspension is a colourless to pale yellow liquid that is clear to slightly cloudy.
Suspenzija je brezbarvna do bledorumena, bistra do nekoliko motna tekočina.
In a clinical study, an increased rate of wheezing was observed in infants and toddlers 12-23 months of age after vaccination (see section 4.8).
V klinični študiji so po cepljenju opazili povečano stopnjo sopenja pri dojenčkih in malčkih starih od 12-23 mesecev (glejte poglavje 4.8).
Summary of adverse reactions
Povzetek neželenih učinkov
Tell your doctor straight away or seek urgent medical care if you experience any of the effects above.
Če opazite kateri koli zgoraj naštet neželeni učinek, nemudoma obvestite svojega zdravnika ali poiščite nujno medicinsko pomoč.
D153-P502 Europe c c
D153-P502 Evropa
Marketing Authorisation Holder: MedImmune, LLC, Lagelandseweg 78, 6545 CG Nijmegen, Netherlands, (Tel) +31 24 371 7310
MedImmune, LLC Lagelandseweg 78 6545 CG Nijmegen Nizozemska (tel) +31 24 371 7310
Talk to your doctor, nurse or pharmacist before vaccination:
Pred cepljenjem se posvetujte s svojim zdravnikom, medicinsko sestro ali farmacevtom:
Contains also: sucrose, dibasic potassium phosphate, monobasic potassium phosphate, gelatin (porcine, Type A), arginine hydrochloride, monosodium glutamate monohydrate, water for injections.
Vsebuje tudi: saharozo, kalijev hidrogenfosfat, kalijev dihidrogenfosfat, želatino (svinjsko, tipa A), argininijev klorid, natrijev glutamat monohidrat, vodo za injekcije.
Fluenz must only be used as a nasal spray.
Cepivo Fluenz se lahko uporablja le v obliki pršila za nos.
QUALITATIVE AND QUANTITATIVE COMPOSITION Reassortant influenza virus* (live attenuated) of the following strains**: A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029)
KAKOVOSTNA IN KOLIČINSKA SESTAVA Novi virus gripe* (živ oslabljen) naslednjih sevov**: A/California/7/2009 (H1N1)pdm09-podoben sev (A/California/7/2009, MEDI 228029)
If any of these apply, tell your doctor, nurse or pharmacist.
Če karkoli od tega velja za vas, obvestite svojega zdravnika, medicinsko sestro ali farmacevta.
Efficacy (95% CI)b Matched strains
Učinkovitost (95-% IZ)b Ujemajoči se sevi
Reassortant influenza virus* (live attenuated) of the following strains**: A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029)
Novi virus gripe* (živ oslabljen) naslednjih sevov**: A/California/7/2009 (H1N1)pdm09-podoben sev (A/California/7/2009, MEDI 228029)
Dibasic potassium phosphate Monobasic potassium phosphate Gelatin (porcine, Type A) Arginine hydrochloride Monosodium glutamate monohydrate Water for injections
6.1 Seznam pomožnih snovi saharoza kalijev hidrogenfosfat kalijev dihidrogenfosfat želatina (svinjska, tip A) argininijev klorid natrijev glutamat monohidrat voda za injekcije
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS PACK SIZE OF 5 SINGLE-USE NASAL APPLICATORS
VELIKOST PAKIRANJA 5 NOSNIKOV ZA ENKRATNO UPORABO
- If any of the side effects gets serious, talk to your doctor, nurse or pharmacist.
- Če katerikoli neželeni učinek postane resen, se posvetujte s svojim zdravnikom, medicinsko sestro ali farmacevtom.
The other ingredients are sucrose, dibasic potassium phosphate, monobasic potassium phosphate, gelatin (porcine, Type A), arginine hydrochloride, monosodium glutamate monohydrate and water for injections.
Pomožne snovi so saharoza, kalijev hidrogenfosfat, kalijev dihidrogenfosfat, želatina (svinjska, tipa A), argininijev klorid, natrijev glutamat monohidrat in voda za injekcije.
The co-administration of FLUENZ with the live attenuated vaccines: measles, mumps, rubella, varicella, and orally-administered poliovirus has been studied.
Preučili so sočasno uporabo cepiva FLUENZ z živimi oslabljenimi cepivi proti ošpicam, mumpsu, rdečkam, noricam in peroralnim cepivom proti otroški paralizi.
METHOD OF ADMINISTRATION For nasal use only.
POSTOPEK UPORABE Samo za nazalno uporabo.
fewer cases than injectable
manj primerov kot pri cepivu, ki se injicira d manj primerov kot pri cepivu, ki se injicira
STATEMENT OF ACTIVE SUBSTANCE(S) Reassortant influenza virus* (live attenuated) of the following strains**: A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029)
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Novi virus gripe* (živ oslabljen) naslednjih sevov**: A/California/7/2009 (H1N1)pdm09-podoben sev (A/California/7/2009, MEDI 228029)
Fluenz nasal spray suspension Influenza vaccine (live attenuated, nasal)
FLUENZ pršilo za nos, suspenzija cepivo proti gripi (z živimi oslabljenimi virusi, nosno)
USA
Združene države Amerike (ZDA)
Method of administration Immunisation must be carried out by nasal administration.
Način uporabe Imunizacija se opravi z nazalno uporabo.
Nasal spray, suspension
FARMACEVTSKA OBLIKA pršilo za nos, suspenzija
Do not pass it on to others.
Napršite v drugo
6 to 35 M 2,107
6 do 35 m 1.616
D153-P513 Asia/ Oceania
D153-P513 Azija/ Oceanija 6 do 35 m 2.107
remove the dose-divider clip from plunger.
Odstranite sponko za razdelitev odmerka Za vnos v drugo nosnico odščipnite in odstranite sponko za razdelitev odmerka z bata.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SINGLE-USE NASAL APPLICATOR
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Packaging Content Package size Withdrawal period
Vrsta ovojnine Vsebina Pakiranje Karenca
EU number Invented name
Izmišljeno ime
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO VPELJATI DRŽAVE ČLANICE
ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
PRILOGA POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO VPELJATI DRŽAVE ČLANICE
ATCvet code: QM01AH90.
ATCvet oznaka: QM01AH90.
4.6 Adverse reactions (frequency and seriousness)*
4.6 Neželeni učinki (pogostost in resnost)*
Tablets can be administered with or without food.
Tablete lahko dajemo s hrano ali brez.
Date of first authorisation: 13/09/2004 Date of last renewal: 29/05/2009
Datum pridobitve dovoljenja za promet: 13.09.2004 Datum podaljšanja dovoljenja za promet: 29.05.2009
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/
Peri-operative pain management.
Peri-operativno obvladovanje bolečine.
Firocoxib is approximately 96 % bound to plasma proteins.
Firokoksib se v približno 96 % veže na plazemske proteine.
4 Chemin de Calquet 31000 Toulouse France
4 chemin du Calquet 31000 TOULOUSE FRANCIJA
The elimination half-life (t½) is 7.59 (± 1.53) hours.
Razpolovna doba izločanja (t½) je 7,59 (± 1,53) ur.
Relief of post-operative pain:
Lajšanje post-operativne bolečine:
Iron oxides (E172) Caramel (E150d)
Železov oksid (E172) Karamel (E150d)
Duration of treatment will be dependent on the response observed.
Čas trajanja zdravljenja je odvisen od odziva.
Very rare (affects less than 1 animal in 10,000)
Redki (prizadenejo 1 do 10 živali od 10.000 živali) Zelo redki (prizadenejo manj kot eno žival od 10.000 živali)
Overdose studies were not conducted in animals over 14 months of age.
Raziskave na psih starejših od 14 mesecev niso bile izvedene.
Manufacturer for the batch release: MERIAL, 4 Chemin du Calquet, 31000 Toulouse, France
Izdelovalec, odgovoren za sprostitev serije: MERIAL, 4 Chemin du Calquet, 31000 Toulouse, Francija
Firocoxib
Firokiksib
10 tablets 30 tablets 60 tablets 180 tablets
10 tablet 30 tablet 60 tablet 180 tablet
If such use cannot be avoided, those dogs require careful veterinary monitoring.
Če se uporabi v takih primerih ne moremo izogniti, je potreben strog veterinarski nadzor.
The chewable tablets (57 mg or 227 mg) are available in the following pack sizes:
Žvečljive tablete (57 mg ali 227 mg) so na voljo v naslednjih pakiranjih:
These reactions are generally of a transitory nature and are reversible when the treatment is stopped.
Te reakcije so običajno prehodnega značaja in minejo, ko prenehamo z zdravljenjem.
Mode of action:
Način delovanja:
The peak concentration (Cmax) is 0.52 (± 0.22) µg/ml (equivalent to approximately 1.5 µM), area under the curve (AUC 0-24) is 4.63 (±1.91) µg x hr/ml, and oral bioavailability is 36.9 (± 20.4) percent.
Najvišja vrednost koncentracije (Cmax) je 0,52 (± 0,22) µg/ml (kar ustreza približno 1,5 µM), površina pod krivuljo (AUC 0-24) je 4,63 (± 1,91) µg xhr/ml, in oralna biorazpoložljivost je 36,9 (± 20,4) %.
For oral use as per table below.
Za peroralno uporabo v skladu s spodaj navedeno tabelo.
Lactose Monohydrate Microcrystalline Cellulose Chartor Hickory Smoke Flavour Hydroxypropyl Cellulose Croscarmellose Sodium Magnesium Stearate Caramel (E150d) Silica, colloidal anhydrous Iron Oxides (E172)
Laktoza monohidrat Celuloza, mikrokristalna Chartor dimni hikori okus Hidroksipropilceluloza Natrijev karmelozat, premreženi Magnezijev stearat Kramel (E150d)
Cyclooxygenase is responsible for generation of prostaglandins.
Ciklooksigenaza je odgovorna za sintezo prostaglandinov.
5 mg/kg once daily.
Enkrat dnevno 5 mg/kg.
Do not use in animals suffering from gastrointestinal bleeding, blood dyscrasia or haemorrhagic disorders.
Ne uporabite pri živalih s krvavitvami v prebavilih, z motnjami v sestavi krvi ali hemoragičnimi obolenji.
5.2 Pharmacokinetic particulars
5.2 Farmakokinetične lastnosti
Previcox tablets are supplied in blisters (transparent PVC /aluminium foil) or in 30 ml or 100 ml high density polyethylene bottles (with polypropylene closure).
Previcox tablete so v pretisnih omotih (prozorni PVC/aluminijasta folija) - ali 30 ml in 100 ml polietilenskih plastičnih vsebnikih (s polipropilenskim pokrovom).
Concomitant treatment with molecules displaying action on renal flow, e.g. diuretics or Angiotensin Converting Enzyme (ACE) inhibitors, should be subject to clinical monitoring.
Sočasno zdravljenje z molekulami, ki vplivajo na pretok skozi ledvice npr. diuretiki ali inhibitorji angiotenzin konvertaze (ACE), mora biti pod strogim veterinarskim nadzorom.
For the reduction of post-operative pain and inflammation, the animals can be dosed starting approximately 2 hours before surgery for up to 3 consecutive days as needed.
Za zmanjšanje post-operativne bolečine in vnetja lahko damo živalim prvi odmerek približno 2 uri pred operativnim posegom in po potrebi nadaljujemo zdravljenje še do 3 zaporedne dni.
Following orthopaedic surgery and depending on the response observed, treatment using the same daily dosing schedule may be continued after the first 3 days, upon judgement of the attending veterinarian.
Po ortopedskih operativnih posegih lahko, glede na opaženo uspešnost zdravljenja bolečine, enako odmerjanje nadaljujemo tudi po prvih treh dneh po posegu po presoji odgovornega veterinarja.
Do not use in animals less than 10 weeks of age or less than 3 kg body weight.
Ne uporabite pri živalih mlajših od 10 tednov in lažjih od 3 kg telesne mase.
Following oral administration in dogs at the recommended dose of 5 mg per kg of bodyweight, firocoxib is rapidly absorbed and the time to maximal concentration (Tmax) is 1.25 (± 0.85) hours.
Po peroralnem dajanju zdravila pri psih v priporočenem odmerku 5 mg na kg telesne mase se firokoksib hitro absorbira in v 1,25 (± 0,85) urah doseže maksimalno koncentracijo(Tmax).
Firocoxib is metabolised predominantly by dealkylation and glucuronidation in the liver.
Firokoksib se presnavlja večinoma z dealkilizacijo in glukoronidacijo v jetrih.
Appropriate laboratory testing is recommended prior to treatment in order to detect subclinical (asymptomatic) renal or hepatic disorders that may predispose to adverse effects.
Pred pričetkom zdravljenja so priporočljive ustrezne laboratorijske preiskave za ugotovitev morebitnih obstoječih subkliničnih (asimptomatskih) ledvičnih ali jetrnih obolenj, ki lahko povečajo možnosti za pojav stranskih učinkov.
Administer 5 mg per kg bodyweight once daily as presented in the table below.
Odmerek je 5 mg na kg telesne mase enkrat dnevno kot je prikazano v spodnji tabeli.
Following multiple oral administrations, the steady state is reached by the third daily dose.
Po večkratnem peroralnem dajanju doseže ustaljeno stanje s tremi dnevnimi odmerki.
Previcox Chewable tablets are scored to facilitate accurate dosing and contain caramel and smoke flavours to facilitate administration to dogs.
Previcox žvečljive tablete omogočajo natančno odmerjanje, okus karamela in dima pa olajša dajanje tablet psom.
As with other NSAIDs, serious adverse effects can occur and, in very rare cases, may be fatal.
Kot pri drugih NSAID se lahko pojavijo resni neželeni učinki, ki so izjemoma lahko smrtni.
- 1 cardboard box containing 10 tablets in one blister - 1 cardboard box containing 30 tablets in three blisters - 1 cardboard box containing 180 tablets in eighteen blisters - 1 cardboard box containing 60 tablets in one bottle
- 1 škatla z 10 tabletami v enem pretisnem omotu - 1 škatla s 30 tabletami v treh pretisnih omotih - 1 škatla s 180 tabletami v 18 pretisnih omotih - 1 škatla s 60 tabletami
Previcox must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Zdravila Previcox ne smete uporabljati skupaj z drugimi NSAID ali glukokortikoidi.
The concentration of firocoxib required to inhibit 50 % of the COX-2 enzyme (i.e., the IC50) is 0.16 (± 0.05) µM, whereas the IC50 for COX-1 is 56 (± 7) µM.
50 odstotno inhibicijo COX-2 encima (t.j IC50) dosežemo s koncentracijo 0,16 (± 0,05) µM firokoksiba, medtem ko IC50 za COX-1 znaša 56 (± 7) µM.
As field studies were limited to 90 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the veterinarian.
Ker se podatki raziskav v praksi nanašajo na omejeno obdobje 90 dni, mora biti dolgotrajno zdravljenje pod veterinarskim nadzorom.
Coxibs therefore display analgesic, anti-inflammatory and antipyretic properties.
Koksibi imajo protibolečinske, protivnetne in anti piretične lastnosti.
In dogs ten weeks of age at the start of treatment at dose rates equal or greater to 25 mg/kg/day (5 times the recommended dose) for three months, the following signs of toxicity were observed: bodyweight loss, poor appetite, changes in the liver (accumulation of lipid), brain (vacuolisation), duodenum (ulcers) and death.
Pri psih, ki so bili ob začetku raziskave stari 10 tednov, so se po treh mesecih prejemanja odmerkov enakih ali višjih od 25 mg/kg/dan (petkratni priporočeni odmerek) pojavila naslednja znamenja toksičnosti: izguba telesne mase, slabši apetit, spremembe v jetrih (nakopičenje lipidov), možganih (vakuolizacija), dvanajstniku (razjede) in pogin živali.